维拉帕米与胺碘酮治疗阵发性室上性心动过速的临床疗效

Clinical effects by verapamil and amiodarone in the treatment of paroxysmal supraventricular tachycardia

目的观察维拉帕米与胺碘酮治疗阵发性室上性心动过速(PSVT)的临床疗效及安全性。方法 79例PSVT患者,随机分为治疗组(41例)和对照组(38例),分别采用维拉帕米和胺碘酮治疗,观察并记录两组用药后转复时间及不良反应。结果两组用药后不良反应发生率比较差异无统计学意义(P>0.05);两组转复成功率和转复平均时间比较差异有统计学意义(P<0.05)。结论维拉帕米和胺碘酮治疗PSVT均可取得较好的临床疗效,但维拉帕米的治疗成功率和转复平均时间优于胺碘酮,可以作为临床治疗PSVT的首选药物之一。

Objective To observe clinical effects and safety by verapamil and amiodarone in the treatment of paroxysmal supraventricular tachycardia（PSVT）. Methods A total of 79 PSVT patients were randomly divided into treatment group（41 cases） and control group（38 cases）,and they received verapamil and amiodarone for treatment respectively. Conversion time and adverse reactions were observed and recorded in both groups after drug administration. Results There was no statistically significant difference of incidence of adverse reactions after drug administration between the two groups（P0.05）. The difference of conversion success rate and average conversion time had statistical significance between the two groups（P0.05）. Conclusion Verapamil and amiodarone can provide good clinical effect in treating PSVT,while verapamil shows better success rate and average conversion time than amiodarone. Verapamil can be taken as one of the preferred drugs in clinical treatment of PSVT.